Silver shield: could a simple dressing cut LVAD infections?

NCT ID NCT05163392

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a silver-coated dressing (Silverlon) could reduce infections where the LVAD driveline exits the body. Twenty-five adults with a new LVAD were randomly assigned to receive either the silver dressing or a standard one. Researchers tracked infection rates, comfort, and cost over a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Silverlon (silver-plated biopatch)

What this could lead to

If it works, this could reduce the risk of serious infections in people with LVADs, improving their quality of life and reducing hospital visits.

What could go wrong

This is a very small pilot study with only 25 participants, so results may not apply to everyone. The dressing might not significantly lower infection rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LVAD (LEFT VENTRICULAR ASSIST DEVICE) DRIVELINE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prosthesis-related infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCSF Parnassus

    San Francisco, California, 94143, United States